The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...

Vor Biopharma, Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. It is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, ...

Vor Systems announced it secured $3 million in pre-seed financing to support the development of its AI-enabled transaction platform built for complex renewable energy deals. The funding round was led ...

With this pivot, Vor Bio is repositioning as a focused, late-stage immunology company with a clinically validated asset, a clear two-indication strategy, and and sufficient capital to fund key ...

As of September 11, 2025, Vor Biopharma Inc. had a $229.9 million market capitalization, putting it in the 30th percentile of companies in the Biotechnology industry. Vor Biopharma Inc. does not have ...

China biotech RemeGen and its new U.S. partner Vor Bio are on a roll with their first-in-class autoimmune treatment telitacicept. Two weeks after RemeGen revealed the success of a China phase 3 trial ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune condition. Vor hit reset in May, after nearly a decade of work on blood ...

Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor’s new-look C-suite.

Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...

Just a month after laying off 147 employees and announcing plans to mull “strategic alternatives,” Vor Biopharma Inc. reported raising $175 million in private placement in public equity financing and ...

The biotech, which in a pivot earlier this year laid off nearly all of its staff, will pay $125 million to gain access to an immune disease drug from China’s RemeGen. PureTech Health and the ...

(Yicai) June 26 -- Chinese drugmaker RemeGen has agreed to license Telitacicept, a treatment for autoimmune diseases, exclusively to Vor Bio outside of China in a deal potentially worth more than USD4 ...